Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
diakine.com

See what CB Insights has to offer

Stage

Acquired | Acquired

About DiaKine Therapeutics

DiaKine Therapeutics, Inc. is a development-stage company commercializing immune modulators such as Lisofylline (LSF) and related oral compounds into therapies for diabetes and related complications. These drugs have the potential to stop the progression of diabetes and reverse damage already caused by the disease.In February 2012, DiaKine Therapeutics was acquired by Islet Sciences. The valuation of DiaKine Therapeutics was undisclosed. Other terms of the deal were not released.

DiaKine Therapeutics Headquarter Location

1414 Sachem Place Suite 3

Charlottesville, Virginia, 22901,

United States

Latest DiaKine Therapeutics News

DiaKine secures funding in quest to stop, reverse damage of diabetes

Apr 11, 2012

Share / Apr 10, 2012 at 2:42 PM A clinical-stage company trying to reverse the damage and stop the progression of diabetes is getting a boost from $1.2 million in grants and a matching round of private funding. DiaKine Therapeutics Inc.’s lead product, Lisofylline , is a synthetic small molecule compound intended to directly enhance the insulin-producing function of islet cells and block the destruction of islet cells by inflammatory agents called cytokines. Preclinical studies have led the company to believe that its compound has the potential to stop the progression of type 1 diabetes without the use of toxic immunosuppressive drug and to reverse damage it’s already caused. The company began a phase 1 clinical trial of Lisofylline in 2009. A call to the company seeking comment on the trial’s progress was not returned. DiaKine has just received $2.1 million in grants from the National Institutes of Health and the Iacocca Foundation, and is also raising a $2.1 million round of capital , according to a recent U.S. Securities and Exchange Commission filing. So far, 17 investors have participated, according to the filing. Advertisement Therapeutics for type 1 diabetes comprise a $2.7 billion market that’s forecast to grow 6 percent annually for the next five years, according to Global Data. Monitoring diet and blood sugar, and taking insulin is still the standard of treatment, but a variety of others are under development. A vaccine being developed at the Massachusetts General Hospital is in phase 2 clinical trials , and Genzyme and Osiris’ stem cell therapy has shown promise in clinical trials. Another company, ViaCyte, is looking to start clinical trials next year for its therapy, which involves slipping an envelope filled with pancreatic cells under the skin. In March, DiaKine was acquired by New York-based Islet Sciences Inc. , a developer of technologies in the field of transplantation therapy for patients with diabetes. DiaKine says its pipeline of drugs to address type 1 diabetes, type 2 diabetes and latent autoimmune diabetes in adults targets a total addressable market of $13 billion. Topics

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DiaKine Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DiaKine Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

D

Diabetes

1,734 items

DiaKine Therapeutics Patents

DiaKine Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/4/2012

Diabetes, Monoclonal antibodies, Autoimmune diseases, Experimental cancer drugs, Indoles

Application

Application Date

10/4/2012

Grant Date

Title

Related Topics

Diabetes, Monoclonal antibodies, Autoimmune diseases, Experimental cancer drugs, Indoles

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.